• A
  • |
  • A
  • Text size

AMA News Room

April 7, 2014

AMA Statement on Naloxone Product Approval

For immediate release:
April 7, 2014

Statement attributed to:
Ardis Dee Hoven, M.D.
President, American Medical Association

"The American Medical Association (AMA) applauds the Food and Drug Administration (FDA) for approving the automatic injector of opioid overdose antidote Naloxone for prescription by physicians. We commend FDA for expediting the approval process to quickly increase access to this medicine which will undoubtedly save lives by reducing death from opioid-related overdose.

"The AMA has been a longtime supporter of increasing the availability of Naloxone for patients, first responders and bystanders who can help save lives and has provided resources to bolster legislative efforts to increase access to this medication in several states. Additionally, we have worked with several national groups, including the National Governors Association, the National Conference of Insurance Legislators and the National Safety Council to increase support for the increased availability of and access to Naloxone.

"The AMA's dedication to reducing deaths from overdose is a part of the organization's broader efforts to combat prescription drug abuse and diversion while at the same time preserving access to medically necessary treatments for pain."

###

Media Contact:
Randi Kahn
AMA Media & Editorial
(202) 789-7442
randi.kahn@ama-assn.org

Follow AMA on and .